Mural Oncology Past Earnings Performance
Past criteria checks 0/6
Mural Oncology's earnings have been declining at an average annual rate of -9.3%, while the Biotechs industry saw earnings growing at 12.3% annually.
Key information
-9.3%
Earnings growth rate
-9.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -78.6% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How Mural Oncology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -207 | 41 | 154 |
| 30 Sep 23 | 0 | -196 | 30 | 154 |
| 30 Jun 23 | 0 | -196 | 28 | 160 |
| 31 Mar 23 | 0 | -193 | 28 | 159 |
| 31 Dec 22 | 0 | -190 | 28 | 157 |
Quality Earnings: MURA is currently unprofitable.
Growing Profit Margin: MURA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if MURA's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare MURA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MURA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: MURA has a negative Return on Equity (-78.63%), as it is currently unprofitable.